Idera Pharmaceuticals, Inc. (IDRA)
Idera Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Exton, PA, US. The stock last traded at $0.42, down 23.04% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.
Idera Pharmaceuticals, Inc. is most often compared with the following Healthcare names: